Skip to Content

Aredia (pamidronate) Disease Interactions

There are 2 disease interactions with Aredia (pamidronate):

Moderate

Pamidronate (Includes Aredia) ↔ Electrolyte Abnormalities

Moderate Potential Hazard, Moderate plausibility

Applies to: Thyroid Disease, Electrolyte Abnormalities

Standard hypercalcemia- related metabolic parameters, such as serum levels of calcium, phosphate, magnesium, and potassium, should be carefully monitored following initiation of therapy with pamidronate. Cases of asymptomatic hypophosphatemia, hypokalemia, hypomagnesemia, and hypocalcemia have been reported. Additionally, some rare cases of symptomatic hypocalcemia (including tetany), have been observed. Patients with a history of thyroid surgery may have relative hypoparathyroidism that may predispose to hypocalcemia with pamidronate.

Moderate

Pamidronate (Includes Aredia) ↔ Renal Dysfunction

Minor Potential Hazard, Low plausibility

Applies to: Renal Dysfunction

Pamidronate has been associated with renal toxicity manifested as deterioration of renal function, and potential renal failure. Due to this risk, single doses of pamidronate disodium should not exceed 90 mg (see manufacturers instructions for appropriate infusion durations). Patients who receive pamidronate should have serum creatinine assessed prior to each treatment. Pamidronate is primarily eliminated intact by the kidney, and the risk of renal adverse reactions may be greater in patients with renal impairment. Caution and regular monitoring (prior to each treatment) is recommended.

References

  1. Machado CE, Flombaum CD "Safety of pamidronate in patients with renal failure and hypercalcemia." Clin Nephrol 45 (1996): 175-9
  2. "Product Information. Aredia (pamidronate)." Novartis Pharmaceuticals, East Hanover, NJ.
  3. Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM, Burckhardt P "Pharmacokinetics of pamidronate in patients with bone metastases." J Natl Cancer Inst 84 (1992): 788-92

Aredia (pamidronate) drug Interactions

There are 190 drug interactions with Aredia (pamidronate)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide